Literature DB >> 26999418

Metastatic osteosarcoma: a challenging multidisciplinary treatment.

Cristina Meazza1, Paolo Scanagatta2.   

Abstract

Osteosarcoma is the most common malignant bone tumor, currently treated with pre-and postoperative chemotherapy in association with the surgical removal of the tumor. About 15-20% of patients have evidence of metastases at diagnosis, mostly in the lungs. Patients with metastatic disease still have a very poor prognosis, with approximately 20-30% of long-term survivors, as compared with 65-70% of patients with localized disease. The optimum management of these patients has not been standardized yet due to several patterns of metastatic disease harboring different prognosis. Complete surgical resection of all sites of disease is mandatory and predictive of survival. Patients with multiple sites of disease not amenable to complete surgery removal should be considered for innovative therapeutic approaches because of poor prognosis.

Entities:  

Keywords:  Chemotherapy; different patterns of disease; genomic complexity; multidisciplinary; surgery; survival; tailored therapy; targeted drugs

Mesh:

Year:  2016        PMID: 26999418     DOI: 10.1586/14737140.2016.1168697

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  97 in total

1.  Immune dysregulation and osteosarcoma: Staphylococcus aureus downregulates TGF-β and heightens the inflammatory signature in human and canine macrophages suppressed by osteosarcoma.

Authors:  Joanne L Tuohy; Jason A Somarelli; Luke B Borst; William C Eward; B Duncan X Lascelles; Jonathan E Fogle
Journal:  Vet Comp Oncol       Date:  2019-10-15       Impact factor: 2.613

2.  Quantitative Primary Tumor Indocyanine Green Measurements Predict Osteosarcoma Metastatic Lung Burden in a Mouse Model.

Authors:  Mitchell S Fourman; Adel Mahjoub; Jon B Mandell; Shibing Yu; Jessica C Tebbets; Jared A Crasto; Peter E Alexander; Kurt R Weiss
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

3.  Downregulation of miR-136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma.

Authors:  Yanchen Chu; Xiaoli Hu; Guangfeng Wang; Zhijie Wang; Yanjin Wang
Journal:  Oncol Lett       Date:  2019-04-01       Impact factor: 2.967

4.  Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1.

Authors:  Zi Li; Jiangdong Ni; Deye Song; Muliang Ding
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

5.  Downregulation of miR-588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma.

Authors:  Tao Yu; Shuang Liang; Tianhong Ma; Weidong Song
Journal:  Exp Ther Med       Date:  2021-04-08       Impact factor: 2.447

Review 6.  Metastasectomy in pediatric patients: indications, technical tips and outcomes.

Authors:  Paolo Scanagatta; Lara Girelli
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

7.  G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of Snail.

Authors:  Zhen Wang; Xiao Chen; Yongqiang Zhao; Yi Jin; Jia Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-20       Impact factor: 4.553

8.  Silencing hsa_circRNA_0008035 exerted repressive function on osteosarcoma cell growth and migration by upregulating microRNA-375.

Authors:  Gu Gong; Zhifeng Han; Wenjun Wang; Qinli Xu; Jingzhe Zhang
Journal:  Cell Cycle       Date:  2020-08-11       Impact factor: 4.534

9.  Necessity of thoracotomy in pulmonary metastasis of osteosarcoma.

Authors:  Erji Gao; Yang Li; Weigang Zhao; Tiancheng Zhao; Xiang Guo; Weiwei He; Weiming Wu; Yonghong Zhao; Yi Yang
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

10.  SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.

Authors:  Branden A Smeester; Nicholas J Slipek; Emily J Pomeroy; Heather E Bomberger; Ghaidan A Shamsan; Joseph J Peterson; Margaret R Crosby; Garrett M Draper; Kelsie L Becklin; Eric P Rahrmann; James B McCarthy; David J Odde; David K Wood; David A Largaespada; Branden S Moriarity
Journal:  Oncogene       Date:  2019-10-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.